AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Conditions: B-cell Malignancy; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma Intervention: Drug: AS-1763 Sponsor: Carna Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2022 Category: Research Source Type: clinical trials